Xeros technology jumps; Tekmar collapses – night match

Xerus Tech achieved the best performance this week after two announcements on Tuesday.

The announcement of the results of independent testing of the clothing technology company’s household washing machine filtration technology, XFilter, was quite impressive, but perhaps it was the licensing agreement for its XFilter technology with Hanning Elektro-Werke that excited the market.

Under the terms of the 10-year non-exclusive agreement, Hanning will manufacture and sell filters that include Xeros’ own XFilter technology.

Xeros Technology was the best performer this week after two announcements on Tuesday

This will enable washing machine manufacturers to offer consumers the ability to easily and safely capture and dispose of more than 90 percent of microfibers, including microplastics, released during washing cycles, Zyros said.

The filters are built into the washer and designed to last the life of the washer.

In the middle of the silver medal this week was Lexington Gold, a gold exploration and development company with projects in North and South Carolina, which the company told investors is in the United States.

Shares rose 24 percent after “exceptional checks” of the 5,000-meter reverse circulation drilling program at the Jones-Keystone project.

Computer game developer and publisher Frontier Developments has apparently regained its magic since the poor release of Elite Dangerous: Odyssey last year.

Shares rose a fifth this week after reporting strong second-half performance and record full-year earnings.

Revenue was boosted by the release of a successful game, Jurassic World Evolution 2, which the company said continued to build player numbers following its launch in November 2021, with approximately 1.3 million base game units available on all platforms were sold – excluding downloads via Microsoft’s Game Pass subscription service (It was added to that platform on May 17).

Scancell Holdings has risen 13 per cent to 14.38 pence, giving it a market value of £ 118 million, after expanding a phase two study of a SCIB1 vaccine for an advanced form of skin cancer – a step that will expand patient numbers and speed up recruitment.

The new cohort in the scope study will consist of people with metastatic melanoma who receive dual checkpoint therapy along with the company’s drug. This “multiplier” consists of the current treatments Yervoy and Opdivo.

Investors have been told that Scancell is still on track to provide preliminary efficiency data this year.

Tekmar Group had the biggest drop of the week, losing nearly three-quarters of its stock market value after the company offered itself for sale, with the board saying it did not have balance sheet power to implement its growth strategy.

The provider of technology and services to global foreign energy markets said current trade remains challenging but is in line with management expectations.

The company showed a half-year loss of £ 3.2 million compared to a loss of £ 2.2 million in the previous year.

The Tekmar Group, a provider of technology and services to global marine energy markets, said current trading remains challenging and sets itself up for sale.

The Tekmar Group, a provider of technology and services to global marine energy markets, said current trading remains challenging and sets itself up for sale.

Digital publisher Devolver Digital halved its share price as it said sales of new computer games in the first five months of the year were slower than expected.

The independent video game company cut its revenue and earnings guidance for the full year due to the poor performance of three of its most invested games, adding that both revenue and earnings will be weighed in the second half of the year.

It is often difficult to reconcile the remarks made in a company’s stock market announcement with the reaction to the stock’s price.

That was the case this week with Verici DX, which lost a third of its value after releasing the latest data on Tuteva, the company’s post-transplant blood test focused on acute rejection.

Additional data show a 60 percent positive predictive value and 80 percent negative predictive value for Tuteva, a next-generation RNA sequencing test.

These data confirm that Tuteva is showing strong performance in detecting acute rejection after kidney transplantation, the company said. These clinically significant findings set Tuteva up for a commercial launch on schedule later this year to support an estimated 100,000 worldwide patients undergoing kidney transplants annually.

The stock is now trading at 18 pence, up from 77.5 a year ago.

Immediate acquisition The remaining cash veneer from Immedia Group’s remains has announced plans to acquire fintech Fininu Holdings, which is considered a reverse acquisition according to AIM rules.

The main reasons for the acquisition are Fianu’s future potential as an innovative Fintech group that will own a… Banking License issued by the Bank of England. The company views Fienu as a customer-centric business model that enhances financial inclusion, a strong experienced leadership team, alternative data analysis and insight, and a forward-looking approach to bringing potentially revolutionary products and services to market, enabled by Open Banking, the company. said.

Shares of Immediate fell 26 percent to 16,625 pence after the company raised £ 8.0 million through a 20-penny share offering.

Some of the links in this article may be affiliate links. If you click on it, we can earn a small commission. It helps us to fund This Is Money and make it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.

Leave a Comment